Soluble CD30 and Cd27 levels in patients undergoing HLA antibody-incompatible renal transplantation

Hamer, 2006, The burden of chronic kidney disease, BMJ, 332, 563, 10.1136/bmj.332.7541.563 Norman, 2005, The kidney transplant wait-list: allocation of patients to a limited supply of organs, Semin Dial, 18, 456, 10.1111/j.1525-139X.2005.00088.x Higgins, 2008, New choices for patients needing kidney transplantation across antibody barriers, J Ren Care, 34, 85, 10.1111/j.1755-6686.2008.00025.x Stegall, 2006, A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody, Am J Transplant, 6, 346, 10.1111/j.1600-6143.2005.01178.x Gwinner, 2007, Renal transplant rejection markers, World J Urol, 25, 445, 10.1007/s00345-007-0211-6 Pelzl, 2002, Soluble CD30 as a predictor of kidney graft outcome, Transplantation, 73, 3, 10.1097/00007890-200201150-00002 Süsal, 2002, Identification of highly responsive kidney transplant recipients using pretransplant soluble CD30, J Am Soc Nephrol, 13, 1650, 10.1097/01.ASN.0000014256.75920.5B Schwab, 1982, Production of a monoclonal antibody specific for Hodgkin and Sternberg–Reed cells of Hodgkin's disease and a subset of normal lymphoid cells, Nature, 299, 65, 10.1038/299065a0 Tarkowski, 2003, Expression and a role of CD30 in regulation of T-cell activity, Curr Opin Hematol, 10, 267, 10.1097/00062752-200307000-00003 Pelzl, 2003, Evaluation of posttransplantation soluble CD30 for diagnosis of acute renal allograft rejection, Transplantation, 75, 421, 10.1097/01.TP.0000044702.18327.66 Slavcev, 2005, Soluble CD30 and HLA antibodies as potential risk factors for kidney transplant rejection, Transpl Immunol, 14, 117, 10.1016/j.trim.2005.03.014 Weimer, 2005, sCD30 and neopterin as risk factors of chronic renal transplant rejection: impact of cyclosporine A, tacrolimus, and mycophenolate mofetil, Transplant Proc, 37, 1776, 10.1016/j.transproceed.2005.02.088 Langan, 2007, Post-transplant HLA class II antibodies and high soluble CD30 levels are independently associated with poor kidney graft survival, Am J Transplant, 7, 847, 10.1111/j.1600-6143.2006.01691.x Rajakariar, 2005, High pre-transplant soluble CD30 levels are predictive of the grade of rejection, Am J Transplant, 5, 1922, 10.1111/j.1600-6143.2005.00966.x Vaidya, 2006, Pretransplant soluble CD30 is a better predictor of posttransplant development of donor-specific antibodies and acute vascular rejection than panel reactive antibodies, Transplantation, 82, 1606, 10.1097/01.tp.0000248530.66421.50 Slavcev, 2007, Soluble CD30 in patients with antibody-mediated rejection of the kidney allograft, Transpl Immunol, 18, 22, 10.1016/j.trim.2007.04.001 Maurer, 1992, IgM and IgG but not cytokine secretion is restricted to the CD27+ B lymphocyte subset, J Immunol, 148, 3700 Agematsu, 1997, B cell subpopulations separated by CD27 and crucial collaboration of CD27+ B cells and helper T cells in immunoglobulin production, Eur J Immunol, 27, 2073, 10.1002/eji.1830270835 Klein, 1998, Human immunoglobulin (Ig)M+IgD+peripheral blood B cells expressing the CD27 cell surface antigen carry somatically mutated variable region genes: CD27 as a general marker for somatically mutated (memory) B cells, J Exp Med, 188, 1679, 10.1084/jem.188.9.1679 Agematsu, 1999, Plasma cell generation from B-lymphocytes via CD27/CD70 interaction, Leuk Lymphoma, 35, 219, 10.3109/10428199909145724 Font, 1996, Elevated soluble CD27 levels in serum of patients with systemic lupus erythematosus, Clin Immunol Immunopathol, 81, 239, 10.1006/clin.1996.0184 Tak, 1996, Expression of the activation antigen CD27 in rheumatoid arthritis, Clin Immunol Immunopathol, 80, 129, 10.1006/clin.1996.0106 van Oers, 1993, Expression and release of CD27 in human B-cell malignancies, Blood, 82, 3430, 10.1182/blood.V82.11.3430.3430 Widney, 1999, Aberrant expression of CD27 and soluble CD27 (sCD27) in HIV infection and in AIDS-associated lymphoma, Clin Immunol, 93, 114, 10.1006/clim.1999.4782 Nakatsuji, 2003, High levels of serum soluble CD27 correlated with renal dysfunction, Clin Exp Med, 2, 192, 10.1007/s102380300006 Montgomery, 2004, Transplanting patients with a positive donor-specific crossmatch: a single center's perspective, Pediatr Transplant, 8, 535, 10.1111/j.1399-3046.2004.00214.x Racusen, 2003, Antibody-mediated rejection criteria — an addition to the Banff 97 classification of renal allograft rejection, Am J Transplant, 3, 708, 10.1034/j.1600-6143.2003.00072.x Chamuleau, 1992, Serum levels of soluble CD27 in renal transplant recipients, Transplantation, 54, 932, 10.1097/00007890-199211000-00033 Nakao, 2002, Serum levels of soluble CD26 and CD30 in patients on hemodialysis, Nephron, 91, 215, 10.1159/000058395 Girndt, 2001, Molecular aspects of T- and B-cell function in uremia, Kidney Int Suppl, 78, S206, 10.1046/j.1523-1755.59.s78.6.x Weimer, 2006, Post-transplant sCD30 and neopterin as predictors of chronic allograft nephropathy: impact of different immunosuppressive regimens, Am J Transplant, 6, 1865, 10.1111/j.1600-6143.2006.01407.x